A single-center prospective randomized controlled trial for tiggio combined with oxaliplatin (SOX) versus capecitabine combined with oxaliplatin (XELOX) in the treatment of postoperative adjuvant chemotherapy in patients with colorectal cancer

ABSTRACT: Interventions: Group 1:SOX;Group 2:XELOX Primary outcome(s): 3 years disease free survival rate Study Design: Randomized parallel controlled trial

DISEASE(S): Colorectal Cancer

PROVIDER: 2681442 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR